(Reuters) - Merck & Co's approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.
![](http://rc.feedsportal.com/r/243249817894/u/419/f/415368/c/871/s/4afb5650/sc/14/rc/1/rc.img)
![](http://rc.feedsportal.com/r/243249817894/u/419/f/415368/c/871/s/4afb5650/sc/14/rc/2/rc.img)
![](http://rc.feedsportal.com/r/243249817894/u/419/f/415368/c/871/s/4afb5650/sc/14/rc/3/rc.img)
![](http://da.feedsportal.com/r/243249817894/u/419/f/415368/c/871/s/4afb5650/sc/14/a2.img)
![](http://pi.feedsportal.com/r/243249817894/u/419/f/415368/c/871/s/4afb5650/sc/14/a2t.img)